Invesco SteelPath業主有限合夥與能源設備主動型ETF PIPE 深 滬
已收盤 02-06 16:00:00 美东时间
26.6232
+0.233
+0.88%
華盛通- 最 高26.6232
- 今 開26.3905
- 成交量 27股
- 最 低 26.6232
- 昨 收 26.3905
- 總市值 5617.50万
- 52周最高 26.6232
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 20.1715
- 委 比 0.00%
- 總股本 211.00万
- 歷史最高 26.6232
- 量 比 0
- 振 幅 0.00%
- 歷史最低 20.1715
- 每 手 1
- 風險率 0.75%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Meet Infleqtion: The Sleeping Giant Quantum Stock Flying Under The Radar — For Now
Infleqtion, formerly ColdQuanta, is an under-the-radar quantum computing and sensing company set to go public in the coming weeks via SPAC merger with well-known Wall Street dealmaker Michael Klein's Churchill Capital Corp X (NASDAQ:CCCX).
02-07 03:18
Chevron's Tengiz problems hurt Kazakhstan's CPC oil exports
Chevron's Tengiz problems hurt Kazakhstan's CPC oil exports MOSCOW/LONDON, Feb 6 (Reuters) - Kazakhstan's planned oil exports could fall by as much as 35% this month via its main route through Russia, four trading sources have told Reuters, as the giant Tengiz oilfield slowly recovers from fires at
02-06 21:39
BUZZ-Street View: Bristol Myers Squibb drug pipeline in focus as key patent expiry looms
BUZZ-Street View: Bristol Myers Squibb drug pipeline in focus as key patent expiry looms ** Bristol Myers Squibb BMY.N on Thursday forecast its 2026 revenue and profit to exceed Wall Street expectations, noting that reduced prices for its blood thinner Eliquis are expected to boost overall sales **
02-06 21:19
Biogen Q4 results beat; forecasts 2026 adj EPS $15.25-$16.25
Biogen Q4 results beat; forecasts 2026 adj EPS $15.25-$16.25 Overview Biotechnology firm's Q4 2025 revenue beat analyst expectations Adjusted EPS for Q4 2025 beat analyst expectations Company expects 2026 revenue to decline by mid-single digit percentage Outlook Biogen expects full-year 2026 revenue
02-06 20:05
MDU Resources Q4 revenue misses estimates
MDU Resources Q4 revenue misses estimates Overview Energy delivery firm's Q4 revenue missed analyst expectations Company acquired 49% stake in Badger Wind Farm Outlook MDU Resources expects 2026 EPS between $0.93 and $1.00 Company plans $560 mln capital investment in 2026 MDU Resources anticipates l
02-05 21:40
BRIEF-Tinybuild Says Rev Slightly Ahead Of Expectations Resulted In Positive EBITDA For H2
BRIEF-Tinybuild Says Rev Slightly Ahead Of Expectations Resulted In Positive EBITDA For H2 Feb 5 (Reuters) - Tinybuild Inc TBLD.L : TINYBUILD, INC. - PRE-CLOSE TRADING UPDATE TINYBUILD INC: PIPELINE FOR 2026 AND BEYOND IS STRONG TINYBUILD: REVENUE SLIGHTLY AHEAD OF EXPECTATIONS RESULTED IN POSITIVE
02-05 15:28
BRIEF-Generate Biomedicines Inc - Announces Initial Public Offering
BRIEF-Generate Biomedicines Inc - Announces Initial Public Offering Feb 4 (Reuters) - GENERATE BIOMEDICINES INC - ANNOUNCES INITIAL PUBLIC OFFERING - SEC FILING GENERATE BIOMEDICINES INC - APPLIES TO LIST ON NASDAQ AS GENB - SEC FILING GENERATE BIOMEDICINES INC - GOLDMAN SACHS & CO,MORGAN STANLEY ,P
02-05 06:59
GRI Bio raises $14.5 mln to fund operations into Q1 2027
GRI Bio raises $14.5 mln to fund operations into Q1 2027 Overview Biotechnology company raised $14.5 mln in gross proceeds to fund operations into Q1 2027 Company announced positive Phase 2a data for GRI-0621 in idiopathic pulmonary fibrosis Cash position expected to fund operations into Q1 2027 Out
02-04 21:56
BRIEF-Pfizer’S Ultra-Long-Acting Injectable Glp-1 RA Shows Weight Loss Results In Phase 2B Trial
BRIEF-Pfizer’S Ultra-Long-Acting Injectable Glp-1 RA Shows Weight Loss Results In Phase 2B Trial Feb 3 (Reuters) - Pfizer Inc PFE.N : PFIZER’S ULTRA-LONG-ACTING INJECTABLE GLP-1 RA SHOWS ROBUST AND CONTINUED WEIGHT LOSS WITH MONTHLY DOSING IN PHASE 2B TRIAL PFIZER’S ULTRA-LONG-ACTING INJECTABLE GLP-
02-03 21:21
Enterprise Products Q4 revenue beats analyst expectations on record volumes
Enterprise Products Q4 revenue beats analyst expectations on record volumes Overview Midstream energy provider's Q4 revenue beat analyst expectations Adjusted EBITDA for Q4 beat analyst expectations Company repurchased $50 mln of common units in Q4 Outlook Enterprise expects organic growth capital i
02-03 19:09
